
Quarterly report 2025-Q4
added 02-10-2026
Electromed Revenue 2011-2026 | ELMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Electromed
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 M | 54.7 M | 48.1 M | 41.7 M | 35.8 M | 32.5 M | 31.3 M | 28.7 M | 25.9 M | 23 M | 19.4 M | 15.5 M | 15.1 M | 19.5 M | 19 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64 M | 15.1 M | 31.6 M |
Quarterly Revenue Electromed
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.9 M | 16.9 M | - | 15.7 M | 16.3 M | 14.7 M | - | 13.9 M | 13.7 M | 12.3 M | - | 12.1 M | 11.7 M | 10.7 M | 22.4 M | 10.1 M | 10.2 M | 10 M | 20.2 M | 8.79 M | 9.5 M | 8 M | 9.5 M | 8 M | 8.55 M | 8.3 M | 8.55 M | 8.3 M | 8.01 M | 7.28 M | 8.01 M | 7.28 M | 6.96 M | 6.3 M | 6.98 M | 6.38 M | 6.37 M | 5.55 M | 6.37 M | 5.55 M | 6.26 M | 5 M | 6.26 M | 5 M | 4.88 M | 4.77 M | 4.88 M | 4.77 M | 3.5 M | 3.42 M | 3.5 M | 3.42 M | 3.86 M | 4.03 M | 3.86 M | 4.03 M | 4.79 M | 5.38 M | 4.79 M | 5.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.4 M | 3.42 M | 8.42 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.0 | -0.58 % | $ 1.62 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.15 | -2.51 % | $ 259 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.35 | -1.05 % | $ 5.42 K | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.71 | -1.44 % | $ 369 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
4 B | $ 168.12 | -2.18 % | $ 12.6 B | ||
|
AxoGen
AXGN
|
225 M | $ 31.05 | -4.87 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.01 | -2.91 % | $ 849 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.69 | 9.81 % | $ 32.4 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.65 | -0.52 % | $ 346 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.35 | -1.93 % | $ 90.8 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.1 | 1.19 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 34.34 | 0.81 % | $ 1.07 B | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.53 | 2.15 % | $ 12.2 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 80.81 | -0.42 % | $ 47.3 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.76 | -7.37 % | $ 1.07 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.8 | 1.25 % | $ 1.61 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | 0.34 % | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.37 | -0.29 % | $ 2.97 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.84 | -0.85 % | $ 69.8 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.48 | 0.22 % | $ 111 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.67 | -4.29 % | $ 28 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M |